Research
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l67 (Published 24 January 2019) Cite this as: BMJ 2019;364:l67
Data supplement
Web extra
- Data Supplement - Supplementary information: eTables1-4 and eFigure 1
Related articles
- Research Methods & Reporting Published: 25 May 2017; BMJ 357 doi:10.1136/bmj.j2250
See more
- Introductory AddressProv Med Surg J October 03, 1840, s1-1 (1) 1-4; DOI: https://doi.org/10.1136/bmj.s1-1.1.1
- Report of the Meeting of the Eastern Branch of the Provincial Association at Bury St. Edmond'sProv Med Surg J October 03, 1840, s1-1 (1) 10-13; DOI: https://doi.org/10.1136/bmj.s1-1.1.10
- Mr. Warburton's Bill for the Regulation of the Medical ProfessionProv Med Surg J October 03, 1840, s1-1 (1) 13-15; DOI: https://doi.org/10.1136/bmj.s1-1.1.13
- An Atlas of Plates, illustrative of the Principles and Practice of Obstetric Medicine and Surgery, with descriptive LetterpressProv Med Surg J October 03, 1840, s1-1 (1) 4; DOI: https://doi.org/10.1136/bmj.s1-1.1.4
- A Practical Treatise on the Diseases peculiar to Women, illustrated by Cases, &cProv Med Surg J October 03, 1840, s1-1 (1) 4-5; DOI: https://doi.org/10.1136/bmj.s1-1.1.4-a
Cited by...
- Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
- Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
- A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases
- Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial
- Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
- Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset
- Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- Inflammation in Heart Failure: JACC State-of-the-Art Review